Index · Artikel · GSK pounces on Human Genome with $2.6 billion bid

GSK pounces on Human Genome with $2.6 billion bid

2012-04-19 3
résuméLONDON Human Genome Sciences has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector recently swept by M&A activity. The U.S. pioneer of gene-based drug discove

GSK pounces on Human Genome with $2.6 billion bid

LONDON Human Genome Sciences has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector recently swept by M&A activity.

The U.S. pioneer of gene-based drug discovery, which sells a new drug for lupus with GSK, said on Thursday the offer of $13 per share, made in a letter on April 11, did not reflect the value inherent in the company.

It has hired Goldman Sachs and Credit Suisse to help explore strategic alternatives, including a possible sale. GSK has been invited to participate in that process.

The Rockville, Maryland-based firm was formed 20 years ago with the mission to isolate genes and identify their function in order to develop new drugs. Over the years it has had a rollercoaster ride as hopes for its drugs have waxed and waned.

GSK's offer represents an 81 percent premium to its closing stock price of $7.17 on Wednesday. However, that is still well below the $30 touched a year ago and investors are hoping for more, with the shares doubling to $14.20 by 1930 GMT.

Britain's biggest drugmaker said the rebuff was disappointing as its offer would give investors "immediate and certain value" superior to what Human Genome could achieve as a standalone company.

GSK chief executive Andrew Witty wrote to Human Genome boss Tom Watkins on April 11 setting out the proposal, saying he was prepared to commence a cash tender offer with no financing or due diligence condition.

Buying Human Genome would give GSK full rights to partnered drugs, which include not only Benlysta - the first new drug for lupus in half a century - but also promising experimental drugs for heart disease and diabetes.

Many drugmakers are seeking to do deals to bolster their pipelines, as older products go off patent, and GSK's readiness to buy Human Genome is a sign of confidence in the drugs that the companies have been developing together.

GSK also expects $200 million in cost synergies by 2015, with the acquisition boosting earnings from 2013.


Cowen & Co analyst Eric Schmidt said GSK was likely to seal a deal in the end.

"The 81 percent premium versus yesterday's close is a big number, and I'm sure GSK is likely to pay a little bit more to get the deal done. I think it's very likely to be sold to GSK at around $15 or so a share," Schmidt said.

"I doubt anyone else will come in. It's going to be hard for another company to pay that sort of a premium not having the inside scoop on Benlysta or on anything else these two companies are collaborating on."

Tim Anderson of Bernstein said outside interest in Human Genome's drugs was possible but any other non-GSK acquirer would only get partial control, which could deter bidders.

Barclays analysts also see no "white knight" counter-bidder on the horizon, even though the deals between GSK and Human Genome have no tricky change-of-control clauses.

GSK has long been rumoured as a potential acquirer of Human Genome, since it has been in partnership with the firm since 1993 and is already collaborating on a number of medicines.

Still, the decision to pull the trigger on a takeover attempt may surprise some investors because GSK management has tended not to buy out partners it is working with in the past.


Analysts said GSK clearly saw value beyond Benlysta.

The two companies are also collaborating on a high-profile experimental heart drug called darapladib, which is in Phase III development, and albiglutide for diabetes, which could be filed for approval late this year or early in 2013.

Mark Clark, an analyst at Deutsche Bank, said darapladib was the biggest ticket pipeline opportunity, with up to $10 billion annual sales potential, although researchers will not know if it actually works until key trial results in 2013 or 2014.

Benlysta, which is subject to a 50:50 profit share deal between the two companies, has got off to a slow start but is still seen as having potential sales of $2.15 billion by 2016, according to consensus forecasts from Thomson Reuters Pharma. A year or so ago investors had been hoping for $3-4 billion.

Despite disappointment about Benlysta sales to date, investors are likely to be emboldened in thinking they can get a better price for their Human Genome shares by recent developments that show Big Pharma's hunger for biotech assets.

Only on Wednesday, Illumina Inc saw off a $6.8 billion bid from Roche Holding AG.

Roche, too, chose to make an unsolicited offer after Illumina shares had fallen back and Sanofi SA took the same approach in its successful acquisition of Genzyme for $20.1 billion last year.

Human Genome said it had asked for more information from GSK about progress with the experimental drugs the two companies have worked on together, including darapladib and albiglutide.

GSK, which is being advised by Lazard and Morgan Stanley, said the plan to acquire Human Genome would not affect its intention to repurchase between 1 billion and 2 billion pounds ($1.6-3.2 billion) in shares in 2012.

Shares in the British-based drugmaker rose nearly 1 percent. ($1 = 0.6238 British pounds)

(Additional reporting by Sophie Sassard, with Lewis Krauskopf and Paritosh Bansal in New York; Editing by David Cowell and Gunna Dickson)


  • Day/
  • Week/
  • Original/
  • Recommand


  • Wie viele mg Folsäure in der pränatalen plus und pränatale 19?

    Patient ist derzeit auf Therobec Plus, können 1 der 2 oben erwähnt ersetzen Therobec? ----schneiden---- In Antwort auf 2010-07-26 21:32 Uhr in suzanne66 Jede Tablette von pränatalen plus enthält 200mcg Folsäure - empfohlene Dosis, 4 täglich. Jede Tab
  • Half of Americans facing diabetes by 2020: report

    Half of Americans facing diabetes by 2020: report
    NEW YORK More than half of Americans will have diabetes or be prediabetic by 2020 at a cost to the U.S. health care system of $3.35 trillion if current trends go on unabated, according to analysis of a new report released on Tuesday by health insurer
  • Hat pyridium Ursache Schlafmangel?

    Seit ca. 2 Wochen der Einnahme dieses und kann nur etwa 4 Stunden oder so schlafen. ----schneiden---- In Antwort auf DzooBaby bei 2011-04-06 12.34 Warum haben Sie diese für ein paar Wochen genommen ?? Normalerweise ist dies Med ist für ein paar Tage
  • US proposes advertisers ditch junk food for kids

    US proposes advertisers ditch junk food for kids
    WASHINGTON The U.S. government on Thursday pressured food companies to cut back on aggressive advertising of junk food to kids, saying it contributes to a serious health crisis facing young Americans. The administration issued proposed voluntary prin
  • Cable News: who cares?

    Cable News: who cares?
    Die jüngsten Nachrichten aus dem ewigen Krieg der Bewertungen unter Nachrichten - Kabelkanälen kommenden schockierend war, habe ich Ihnen sagen, nur schockierend : CNN, die vor drei Jahrzehnten das ganze Geschäft von Cable News erfunden, ist jetzt to
  • Die Beurteilung Alkoholkonsum bedingte Störungen

    Die Beurteilung Alkoholkonsum bedingte Störungen
    Wenn Sie sich in jede Art von Alkohol oder Drogenbehandlungsprogramm werden, eines der ersten Dinge, die eine Einschätzung Ihrer Alkoholproblem passiert ist. Egal, ob Sie freiwillig sind eine langfristige Wohnbehandlungsanlage, eine ambulante Program
  • Top-Marathons für Wanderer

    Top-Marathons für Wanderer
    Diese Marathons schließen diejenigen ein, die für die Läufer in erster Linie konzipiert sind, jedoch auch willkommen Wanderer und haben einen Cut-off-Zeit großzügig genug, um Wanderer aufzunehmen und laufen / Wanderer. Dazu gehören auch Marathons, di
  • Was sind die Nebenwirkungen von Telmisartan Tabletten?

    Ich habe einen hypertention & Arzt Beratung Telma 80 H & stamlo beta 1 Tab pro Tag. Mein BP ist 160/100 hg mm bitte leite mich über Abnahme BP ----schneiden---- In Antwort auf nurse1949 bei 2013.09.29 06.56 Ich bin nicht vertraut mit dem Medikamen
  • Cytotec - Im von 8 Tagen nach meiner Zeit verzögert sollte beginnen ,, ich habe seine Schätzung eine 3 Wochen ab

    ... das? ----schneiden---- In Antwort auf DzooBaby bei 2014.01.29 19.47 Warum in aller Welt würden Sie nehmen nur ein Medikament, das gefährlich, ohne zu wissen, wenn Sie schwanger sind? Warum in Gottes Namen würden Sie nicht testen, um selbst zu seh
  • Wie die politische Partei des Präsidenten Beeinflusst Säuglingssterblichkeit

    Wie die politische Partei des Präsidenten Beeinflusst Säuglingssterblichkeit
    Obwohl die Kindersterblichkeit in den Vereinigten Staaten um 77 Prozent in den letzten 50 Jahren zurückgegangen ist (von 25,2 pro 1000 Geburten in 1963 bis 5,9 im Jahr 2013), ist die USA immer noch schlechter in dieser Abteilung als in vielen anderen